161 related articles for article (PubMed ID: 36289459)
1. Metabolomics analysis of type 2 diabetes remission identifies 12 metabolites with predictive capacity: a CORDIOPREV clinical trial study.
Mora-Ortiz M; Alcala-Diaz JF; Rangel-Zuñiga OA; Arenas-de Larriva AP; Abollo-Jimenez F; Luque-Cordoba D; Priego-Capote F; Malagon MM; Delgado-Lista J; Ordovas JM; Perez-Martinez P; Camargo A; Lopez-Miranda J
BMC Med; 2022 Oct; 20(1):373. PubMed ID: 36289459
[TBL] [Abstract][Full Text] [Related]
2. A set of miRNAs predicts T2DM remission in patients with coronary heart disease: from the CORDIOPREV study.
Rangel-Zuñiga OA; Vals-Delgado C; Alcala-Diaz JF; Quintana-Navarro GM; Krylova Y; Leon-Acuña A; Luque RM; Gomez-Delgado F; Delgado-Lista J; Ordovas JM; Perez-Martinez P; Camargo A; Lopez-Miranda J
Mol Ther Nucleic Acids; 2021 Mar; 23():255-263. PubMed ID: 33425484
[TBL] [Abstract][Full Text] [Related]
3. Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy.
Shang X; Zhong X; Tian X
Tumour Biol; 2016 Aug; 37(8):11163-75. PubMed ID: 26935059
[TBL] [Abstract][Full Text] [Related]
4. Plasma lipidic fingerprint associated with type 2 diabetes in patients with coronary heart disease: CORDIOPREV study.
Villasanta-Gonzalez A; Mora-Ortiz M; Alcala-Diaz JF; Rivas-Garcia L; Torres-Peña JD; Lopez-Bascon A; Calderon-Santiago M; Arenas-Larriva AP; Priego-Capote F; Malagon MM; Eichelmann F; Perez-Martinez P; Delgado-Lista J; Schulze MB; Camargo A; Lopez-Miranda J
Cardiovasc Diabetol; 2023 Aug; 22(1):199. PubMed ID: 37537576
[TBL] [Abstract][Full Text] [Related]
5. Early metabolic markers identify potential targets for the prevention of type 2 diabetes.
Peddinti G; Cobb J; Yengo L; Froguel P; Kravić J; Balkau B; Tuomi T; Aittokallio T; Groop L
Diabetologia; 2017 Sep; 60(9):1740-1750. PubMed ID: 28597074
[TBL] [Abstract][Full Text] [Related]
6. Serum Untargeted Metabolomics Reveal Potential Biomarkers of Progression of Diabetic Retinopathy in Asians.
Wang Z; Tang J; Jin E; Zhong Y; Zhang L; Han X; Liu J; Cheng Y; Hou J; Shi X; Qi H; Qian T; Yuan L; Hou X; Yin H; Liang J; Zhao M; Huang L; Qu J
Front Mol Biosci; 2022; 9():871291. PubMed ID: 35755823
[No Abstract] [Full Text] [Related]
7. MiRNAs profile as biomarkers of nutritional therapy for the prevention of type 2 diabetes mellitus: From the CORDIOPREV study.
Jimenez-Lucena R; Alcala-Diaz JF; Roncero-Ramos I; Lopez-Moreno J; Camargo A; Gomez-Delgado F; Quintana-Navarro GM; Vals-Delgado C; Rodriguez-Cantalejo F; Luque RM; Delgado-Lista J; Ordovas JM; Perez-Martinez P; Rangel-Zuñiga OA; Lopez-Miranda J
Clin Nutr; 2021 Mar; 40(3):1028-1038. PubMed ID: 32723508
[TBL] [Abstract][Full Text] [Related]
8. Plasma metabolites associated with type 2 diabetes in a Swedish population: a case-control study nested in a prospective cohort.
Shi L; Brunius C; Lehtonen M; Auriola S; Bergdahl IA; Rolandsson O; Hanhineva K; Landberg R
Diabetologia; 2018 Apr; 61(4):849-861. PubMed ID: 29349498
[TBL] [Abstract][Full Text] [Related]
9. Metabolic profiling of pre-gestational and gestational diabetes mellitus identifies novel predictors of pre-term delivery.
Diboun I; Ramanjaneya M; Majeed Y; Ahmed L; Bashir M; Butler AE; Abou-Samra AB; Atkin SL; Mazloum NA; Elrayess MA
J Transl Med; 2020 Sep; 18(1):366. PubMed ID: 32972433
[TBL] [Abstract][Full Text] [Related]
10. Study on plasmatic metabolomics of Uygur patients with essential hypertension based on nuclear magnetic resonance technique.
Zhong L; Zhang JP; Nuermaimaiti AG; Yunusi KX
Eur Rev Med Pharmacol Sci; 2014; 18(23):3673-80. PubMed ID: 25535139
[TBL] [Abstract][Full Text] [Related]
11. [Screening of serum oxysterol biomarkers for colon cancer by liquid chromatography-tandem mass spectrometry].
Ma Z; Li Z; Wang H; Wang R; Han X
Se Pu; 2022 Jun; 40(6):541-546. PubMed ID: 35616199
[TBL] [Abstract][Full Text] [Related]
12. Altered Caffeine Metabolism Is Associated With Recurrent Hypoglycemia in Type 2 Diabetes Mellitus: A UPLC-MS-Based Untargeted Metabolomics Study.
Lijing W; Sujie K; Linxi W; Lishan H; Liqin Q; Zhidong Z; Kejun W; Mengjun Z; Xiaoying L; Xiaohong L; Libin L
Front Endocrinol (Lausanne); 2022; 13():843556. PubMed ID: 35784552
[TBL] [Abstract][Full Text] [Related]
13. Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases.
Dawiskiba T; Deja S; Mulak A; Ząbek A; Jawień E; Pawełka D; Banasik M; Mastalerz-Migas A; Balcerzak W; Kaliszewski K; Skóra J; Barć P; Korta K; Pormańczuk K; Szyber P; Litarski A; Młynarz P
World J Gastroenterol; 2014 Jan; 20(1):163-74. PubMed ID: 24415869
[TBL] [Abstract][Full Text] [Related]
14. Metabolomics-based multidimensional network biomarkers for diabetic retinopathy identification in patients with type 2 diabetes mellitus.
Zuo J; Lan Y; Hu H; Hou X; Li J; Wang T; Zhang H; Zhang N; Guo C; Peng F; Zhao S; Wei Y; Jia C; Zheng C; Mao G
BMJ Open Diabetes Res Care; 2021 Feb; 9(1):. PubMed ID: 33593748
[TBL] [Abstract][Full Text] [Related]
15. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
Weng J
J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
[TBL] [Abstract][Full Text] [Related]
16. Value of simple clinical parameters to predict insulin resistance among newly diagnosed patients with type 2 diabetes in limited resource settings.
Wasana KGP; Attanayake AP; Weerarathna TP; Jayatilaka KAPW
PLoS One; 2021; 16(3):e0248469. PubMed ID: 33788827
[TBL] [Abstract][Full Text] [Related]
17. Beta cell functionality and hepatic insulin resistance are major contributors to type 2 diabetes remission and starting pharmacological therapy: from CORDIOPREV randomized controlled trial.
Roncero-Ramos I; Gutierrez-Mariscal FM; Gomez-Delgado F; Villasanta-Gonzalez A; Torres-Peña JD; Cruz-Ares S; Rangel-Zuñiga OA; Luque RM; Ordovas JM; Delgado-Lista J; Perez-Martinez P; Camargo A; Alcalá-Diaz JF; Lopez-Miranda J
Transl Res; 2021 Dec; 238():12-24. PubMed ID: 34298148
[TBL] [Abstract][Full Text] [Related]
18. Novel Biomarkers to Distinguish between Type 3c and Type 2 Diabetes Mellitus by Untargeted Metabolomics.
Jimenez-Luna C; Martin-Blazquez A; Dieguez-Castillo C; Diaz C; Martin-Ruiz JL; Genilloud O; Vicente F; Del Palacio JP; Prados J; Caba O
Metabolites; 2020 Oct; 10(11):. PubMed ID: 33105675
[TBL] [Abstract][Full Text] [Related]
19. Integrated biomarker for type 2 diabetes mellitus and impaired fasting glucose based on metabolomics analysis using ultra-high performance liquid chromatography quadrupole-Orbitrap high-resolution accurate mass spectrometry.
Long J; Liu L; Jia Q; Yang Z; Sun Z; Yan C; Yan D
Rapid Commun Mass Spectrom; 2020 Jun; 34(12):e8779. PubMed ID: 32159245
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
